The prognostic value pf p53, C-erb B-2 and Ki67 in Ovarian Carcinoma;Valor prognostico das proteinas p53, C-ERB-2 e Ki67 no carcinoma do ovario

Acta Medica Portuguesa

Volumn 14, Issue 3, 2001, Pages 277-283

  Frutuoso, Cristina ^a   Silva, Mário Rui ^a   Amaral, Natália ^a   Martins, Irene ^a   De Oliveira, Carlos ^a   De Oliveira, Henrique Miguel ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CHEMISTRY; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MIDDLE AGED; MORTALITY; OVARY TUMOR; PROGNOSIS; PROTO ONCOGENE; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035347387     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. FELIX WONG WS, TATTERSALL MHN: Immunohistochemical determination of tumor growth fraction in human ovarian carcinoma. Br J Obst Gynaecol 1989;96:720-724
2. LEVES-UE AM. kATSAROS D. YU H AI et al: Mutant p53 Protein Overexpression is Associated with Poor outcome in Patients with Well and Moderate Differentiated Ovarian Carcinoma. Cancer 1 995;75: 1327-38
3. SHARP F, MASON WP. CREASMAN W: Ovarian cancer. Biology, diagnosis and management. 1st edition, 1992, Ed Chapman & Hall Medical,London, page 23
4. LANE DP, BENCHIMOL S: p53: Oncogene or Anti-oncogene? Genes Dev 1990;4:18
5. LEVINE AJ, MOMAND J, FINLEY CA: The p53 Tumor Supressor Gene. Nature 1991;351:453-456
6. MARKS IR, DAVIDOFF AM, KERNS BJ et al: Overexpression and Mutation of p53 Epithelial Ovarian Cancer. Cancer Research 1991;51:2979-2984
7. HARLOZINSKA A, BAR JK, SEDLACZEK P, BERGER AI: Expression of p53 e ki67 Reactivity in Ovarian Neoplasms. Am J Cím Pathol 1996;105:334-340
8. CIRISANO FD, KAREAN BY: The role of HER2/neu oncogene in gynecologic cancers. J Society Gynecol Invest 1996;3(3):99-105
9. SLAMON DJ, GODOLPHIN W, JONES CA:Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712
10. SHARP F, MASON WP, CREASMAN W: Ovarian cancer. Biology, diagnosis and management. Istedition, 1992, Ed Chapman & Hall Medical,London, page 208
11. BFREK IS, HACKER NF: Gynecologic neoplasms. Ovary and fallopian tubes. Cap 53. In: Haskell CM, edts. Cancer Treatment. Philadelphia: W. B. Saunders Company, page 628-661
12. OMURA GA, BRADY MF, HOMESLEY CR: Long term follow up and prognostic factor analysis in advanced ovarian cancer: the Gynecologic Oncology Group Experience. J Clin Oncol 1991;9:1138-1150
13. SHARP F, MASON WP, CREASMAN W: Ovarian cancer. Biology, diagnosis and management. 1st edition, 1992, Ed Chapman & Hall Medical,London, page 347
14. MOK K, TSAO SW, NAPP RC: Unifocal origin of advanced human epithelial ovarian cancer. Cancer Res 199652:5119-5122
15. LEE JH, KANG YS, PARK SP et al: p53 Mutation in Epithelial Ovarian Carcinoma and Borderline Ovarian Tumor. Cancer Genet Cytogenet 1995;85:43-50
16. FELIP E, DEL CAMPO MJ, RUBIO D et al: Overexpression of c-erb-2 in Epithelial ovarian cancer. Cancer 1995; 75:2147-52
17. TISHLER RB, CALDERWOOD SK, COLEMAN CN: Increases in sequences specific DNA binding by p53 following treatment chemotherapeutic and DNA damaging agents. Cancer Res 1993;53:2212-2216
18. kUPRYJANCZYK J, BELL D, YANDELL D, SCULLY R, THOR A: p53 Expression in Ovarian Borderline Tumors and Stage 1 Carcinomas. Am J Clin Pathol 1994;102:671-676
19. KHOLER MF, KERNS MB, HUMPHREY PA, MARKS JR, BAST RC, BERCHUCK A: Mutation and Overexpression of p53 in Early Stage Epithelial Ovarian Cancer. Obstet Gynecol 1993; 81: 643-50
20. KUPRYJANCZYK J, THOR A, BEANCHAMP R: p53 gene mutation and protem accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993; 90:4961-4965
21. KLEMI PJ, TAKAHASHI S, JOENSUU H, KIILHOLMA P, NARIMATSU E, MORI M:Immunohistochemical Detection of p53 in Borderline and Malignant Serous Ovarian Tumors.Intern J Gynecol Pathol 1994; 13:228-233
22. HARTMANN LC, PODRATZ KC, KEENEY GL et al:Prognostic Significance of p53 Immunostaining in Epithelial Ovarian Cancer.J Clin Oncol 1994;12:64-69
23. NIWA K, ITOH M, MURASE T et al: Alteration of p53 gene in ovarian carcinoma clinicopathological correlation and prognostic significance. Br J Cancer 1994;70:1191-1197
24. BOSARI S, VIALLE G, RODAELLI U, BOSSI P, BONOLDI E, COGGI G: p53 Accumulation in Ovarian Carcinomas and Its Prognostic Implications. Hum Pathol 1993;24:1175-1179
25. RUBIN SC, FINSTAD CL, WONG GY, ALMADRONES L, PLANTE M, LLOYD K: Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 1993;168:162-9
26. VOLM M, BRUGGERMANN A, GUNTHER M:Diagnostic relevance of ploidy. proliferation and resistance predictive tests in ovarian carcinomas. Cancer Res 1985;45:5180-5
27. BRESCIA RJ,BARAKAT RA, BELLER U:The prognostic significance of nuclear DNA in malignant epithelial tumour of the ovary. Cancer 1990;65:141-7
28. ERBA E, UBEZIO P, PEPE S:Flow cytometric analysis of DNA content in humam ovarian cancer. Br J Cancer 1989;60:45-50
29. KERNS BJ, JORDAN PA, FAERMAN LL:Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative analysis. Am J Clin Pathol 1994;101: 192-197
30. GOFF BA, SHY K, GREER BE, MUNTZ HG, SKELLY M, GOWN AM: Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53. ki-67 and tumor necrosis factor alpha in epithelial ovarian cancer. Eur J Gynecol Oncol 1996;17(6):487-92